Cited by 207Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsLiver Diseases and Immunity

The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

Díaz, Luis Antonio, Arab, Juan Pablo, Louvet, Alexandre, Bataller, Ramón, Arrese, Marco·2023·Nature Reviews Gastroenterology & Hepatology

DOI 10.1038/s41575-023-00822-y

Open this paper in CoChat — free account

Abstract

Nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are the leading causes of chronic liver disease worldwide. NAFLD and ALD share pathophysiological, histological and genetic features and both alcohol and metabolic dysfunction coexist as aetiological factors in many patients with hepatic steatosis. A diagnosis of NAFLD requires the exclusion of significant alcohol consumption and other causes of liver disease. However, data suggest that significant alcohol consumption is often under-reported in patients classified as having NAFLD and that alcohol and metabolic factors interact to exacerbate the progression of liver disease. In this Review, we analyse existing data on the interaction between alcohol consumption and metabolic syndrome as well as the overlapping features and differences in the pathogenesis of ALD and NAFLD. We also discuss the clinical implications of the coexistence of alcohol consumption, of any degree, in patients with evidence of metabolic derangement as well as the use of alcohol biomarkers to detect alcohol intake. Finally, we summarize the evolving nomenclature of fatty liver disease and describe a recent proposal to classify patients at the intersection of NAFLD and ALD. We propose that, regardless of the presumed aetiology, patients with fatty liver disease should be evaluated for both metabolic syndrome and alcohol consumption to enable better prognostication and a personalized medicine approach.

Integrity signals

Registry

Crossref · 10.1038/s41575-023-00822-y

Cites

253 of 253 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citation
Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Griswold, M. G., Fullman, N., Hawley, C., Arian, N., Zimsen, S. R. M., Tymeson, H. D., Venkateswaran, V., Tapp, A. D., Forouzanfar, M. H., Salama, J. S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31310-2 · Cited by 3,524
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citation
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citation
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citation
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 5×
“Alcohol intake can be broadly classified as mild (up to 20 g (women) and 30 g (men) per day), moderate (21–39 g (women) and 31–59 g (men) per day), or heavy (≥40 g (women) and ≥60 g (men) per day) 9 .”
BackgroundInfluential
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002

Show all 252 references

Research works printed but not linked: 2

Hajduch, E., Lachkar, F., Ferré, P. & Foufelle, F. Roles of ceramides in non-alcoholic fatty liver disease. J. Clin. Med. Res. 10, 792 (2021).
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).

Sorted by citations

Items 101–200 of 206

The versatile interplay between steatotic liver disease and liver cancer
Rahbari, M., Gris‐Oliver, A., Ramadori, P., Aicher, D., Sia, D., MALEK, N. P., Loomba, R. S., Bataller, R. A., Llovet, J. M., & Heikenwälder, M. F. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00918-y · Cited by 4
Self-citation
Alcohol-Related Liver Disease
Krag, A. A., Åberg, F., Mellinger, J. L., Lee, B. P., & Israelsen, M. E. (2026) · JAMA · doi:10.1001/jama.2026.12038 · Cited by 7
Donor Atheromatous Disease is a Risk Factor for Hepatic Artery Thrombosis After Liver Transplantation
Zamora, J., Tejero‐Jurado, R., Alañón-Martínez, P. E., Prieto‐Torre, M., Rodriguez-Medina, C., Montero, J. L., Sánchez‐Frías, M., Briceño, J., Ciria, R., Barrera, P., et al. (2024) · Clinical Transplantation · doi:10.1111/ctr.15405 · Cited by 4
Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
Llamoza-Torres, C. J., Fuentes-Pardo, M., & Ramos‐Molina, B. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.64 · Cited by 6
Pro-Opiomelanocortin and Melanocortin Receptor 3 and 4 Mutations in Genetic Obesity
Yanık, T., & Durhan, S. T. (2025) · Biomolecules · doi:10.3390/biom15020209 · Cited by 4
Clinical Trial to Assess the Safety and Tolerability of Anti‐ IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol‐Associated Liver Disease
Díaz, L. A., Morris, S., Dave, S., Kim, S. M., Sarik, W., Richards, L., Madamba, E. V., Bettencourt, R., Fulinara, C., Pham, T. T. T., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70026 · Cited by 4
Self-citation
Risk of Serious Bacterial and Non‐Bacterial Infections in People With MASLD
Targher, G., Tilg, H., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70059 · Cited by 6
Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022
Nakahata, Y., Miwa, T., Obora, A., Kojima, T., Yagi, N., & Shimizu, M. (2025) · Liver International · doi:10.1111/liv.70454 · Cited by 4
Iron deposits in alcoholic and metabolic liver disease
Aguado, D. M., & Martí‐Bonmatí, L. (2023) · ANALES RANM · doi:10.32440/ar.2023.140.03.doc01 · Cited by 4
Short-term high-fat diet feeding plus acute ethanol binge induced acute liver injury in mice via oxidative stress, inflammation and pyroptosis
Deng, Y., Chen, X., Guo, W., Chen, Y., Xu, L., Suo, W., Liu, W., Dai, J., Wang, K., Li, Q., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1602280 · Cited by 3
Metabolic Impact of Alcohol Consumption in MASLD: Understanding MetALD and Beyond
Juárez-Hernández, E., Berrospe-Alfaro, M., Uribe, M., & López-Méndez, I. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103114 · Cited by 3
The nomenclature of fatty liver disease and its impact on obesity traits, insulin resistance, and hepatic fibrosis
Xiang, L., Li, X., Gong, J., He, L., Li, W., Chen, J., Feng, R., Du, S., & Ye, W. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02736-x · Cited by 3
Progression of FIB-4 index predicts major adverse cardiovascular events in patients with metabolic dysfunction
Idalsoaga, F. J., Cambindo, V., Fuentes–López, E., Dukes, E., Ibañez, S., Hunfan, P., Mollo, C., Gonzalez, J., Ayares, G., Ramírez, C., et al. (2025) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502608 · Cited by 3
Self-citation
Spatiotemporal burden, risk factors, and genetic causality of non‐alcoholic fatty liver disease and type 2 diabetes mellitus comorbidity in Europe: A multi‐database analysis
Hu, H., Wang, G., Liang, Y., Liu, Y., Zhao, H., & Yang, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70398 · Cited by 4
Functional roles and regulatory mechanisms of paeonol in the treatment of liver disease
Shu, M. Z., Fang, M., Xu, T., & Yan, Q. (2026) · Natural Products and Bioprospecting · doi:10.1007/s13659-025-00554-3 · Cited by 3
Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patients
Hwang, S. Y., Hsieh, P., Díaz, L. A., Goodman, R. P., Schaefer, E. A. K., Wong, R. J., Luther, J., & Zhang, W. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003162 · Cited by 4
Self-citation
Liver, Cardiovascular and Infectious Outcomes in Alcohol‐Associated Liver Disease With Cardiometabolic Risk Factors
Danpanichkul, P., Duangsonk, K., Pang, Y.-F., Rakwong, K., Jit-Are-Roon, P., Wattanachayakul, P., Srikulmontri, T., Nah, B., Chen, V. L., Kim, D., et al. (2026) · Liver international (Print) · doi:10.1111/liv.70575 · Cited by 1
Global multicenter validation of noninvasive fibrosis assessment pathways in MetALD and ALD
Gu, H., Díaz, L. A., Baeza, N., Idalsoaga, F. J., Zhou, X., Zheng, M., Maiwall, R., Sarin, S. K., Kulkarni, A. V., Ramyasri, R., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001020 · Cited by 3
Self-citation
From consumption to withdrawal: A broad synopsis of the effects of alcohol
Zhu, J., Liu, Q., Kong, B., Shuai, W., Xiao, Z., Dai, C., & Huang, H. (2023) · Medicine Advances · doi:10.1002/med4.46 · Cited by 4
Medical Implications of Renaming Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Choi, Y., & Son, C. (2025) · 대한한의학회지 · doi:10.13048/jkm.25016 · Cited by 3
Steatotic liver disease: what role does alcohol consumption play?
Testino, G., Fucile, C., Gnocchi, M., Rosa, G. M., & Caputo, F. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09726-5 · Cited by 3
A landscape of liver cirrhosis and transplantation in Mexico: Changing leading causes and transplant as response
Lara, I. P., Ortiz‐López, M. G., Bonilla‐Delgado, J., Pérez-Escobar, J., Godínez-Aguilar, R., Luévano‐Contreras, C., Espinosa-García, A. M., Duran, J. P., Alonso-Themann, P. G., Nolasco‐Quiroga, M., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101562 · Cited by 5
Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
Åström, H., Lageborn, C. T., & Hagström, H. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2468297 · Cited by 3
Serum β-klotho is a potential biomarker for diagnosing alcoholic liver disease and differentiating from nonalcoholic fatty liver disease
Fang, C., Miao, X., Peng, C., Xie, Z., Zhao, F., Chen, T., Zhang, W., Bi, X., An, X., & Wu, G. (2025) · PeerJ · doi:10.7717/peerj.19779 · Cited by 2
Physiological Mechanisms Vulnerable to Alcohol‐Induced Alterations: Role in Chronic Comorbidities
Simon, L., Couvillion, K. E., Donovan, M. E., Gallegos, E. M., Souza‐Smith, F. M., & Molina, P. E. (2025) · Comprehensive physiology · doi:10.1002/cph4.70057 · Cited by 4
Impact of diabetes and obesity on patient outcomes in alcohol-associated liver disease: Analysis of 3 databases
Blaney, H. L., Zhang, W., Bandhari, P., Elfeki, M. A., Xie, C., Dunn, W., Wong, R. J., Younossi, Z. M., Kuo, Y., Kong, M., et al. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.09.020 · Cited by 2
Alcohol and Metabolic Stress Synergize to Dysregulate Mitochondrial Health and Lipid Metabolism; Evidence from a Hepatocyte Spheroid Model
Gallegos, E. M., Couvillion, K. E., Darden, D., Rodríguez‐Graciani, K. M., Molina, P. E., & Simon, L. (2025) · Function · doi:10.1093/function/zqaf049 · Cited by 2
Treatment approaches for alcohol use disorder with metabolic dysfunction
Wagner, A. C., Jung, J., Pacher, P., & Lohoff, F. W. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108957 · Cited by 4
The association between organophosphate pesticide residue exposure and non-alcoholic fatty liver disease: A systematic review
Mohamadi, B., Ostadan, M. T., Shokri, S., Bakhtiyari, A., Rasooli, R., Sadighara, P., & Bekheir, S. A. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102216 · Cited by 4
MetALD at the crossroads of metabolic and alcohol-related liver disease
Ayares, G., Díaz, L. A., Arab, J. P., & Arrese, M. A. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.01.008 · Cited by 2
Self-citation
Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment
Kozlitina, J., Romeo, S., & Hobbs, H. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001758 · Cited by 2
Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams
Alexopoulos, A., & Cusi, K. J. (2026) · Diabetes Care · doi:10.2337/dci26-0019 · Cited by 2
Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications
Díaz, L. A., Pose, E., Israelsen, M. E., & Loomba, R. S. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01240-6 · Cited by 3
Self-citation
Alcohol-related liver and extrahepatic malignancies: burden of disease and socioeconomic disparities in 2019
Danpanichkul, P., Suparan, K., Chaiyakunapruk, N., Auttapracha, T., Kongarin, S., Wattanachayakul, P., Ramadoss, V., Suenghataiphorn, T., Sukphutanan, B., Pang, Y., et al. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002882 · Cited by 2
Self-citation
Aldehydes, mitophagy, and the pathogenesis of alcohol-associated and metabolic dysfunction-associated steatohepatitis
Lemasters, J. J., & Zhong, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15260-3.00026-0 · Cited by 2
Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Authors' reply
Danpanichkul, P., Tothanarungroj, P., Díaz, L. A., Arab, J. P., Liangpunsakul, S., & Wijarnpreecha, K. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18250 · Cited by 2
Self-citation
Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021”
Danpanichkul, P., Díaz, L. A., Suparan, K., Wijarnpreecha, K., & Arab, J. P. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0166 · Cited by 2
Self-citation
In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-associated Steatotic Liver Disease
Bao, Q., Zhang, X., Chen, Y., Wang, T., & Siqin, B. (2024) · Journal of Visualized Experiments · doi:10.3791/66810 · Cited by 1
Public Health Policies and Strategies to Prevent Alcohol-Related Morbidity and Mortality
Zibaoui, R. E., Díaz, L. A., Idalsoaga, F. J., & Arab, J. P. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00688-5 · Cited by 1
Self-citation
An Overview of Non-alcoholic Fatty Liver Diseases (NAFLD)
Kang, J., Kim, H.-J., Lim, S.-J., Lee, S., & Hwang, I. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010672 · Cited by 1
Impact of weight loss and lifestyle modifications on liver fibrosis in MASLD and MetALD: A cohort study
Ichikawa, T., Miuma, S., Yamashima, M., Yamamichi, S., Koike, M., Nakano, Y., Yajima, H., Miyazaki, O., Ikeda, T., Okamura, T., et al. (2025) · Biomedical Reports · doi:10.3892/br.2025.2036 · Cited by 1
The Interplay Between Alcohol Consumption and Cardiometabolic Risk Factors in Individuals With MASLD and MetALD
Yeo, Y. H., Rui, F., Zhu, Y., Xu, X., Ma, X., Ni, W., Sun, Y., Hu, X., Wu, C., Shi, J., et al. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70015 · Cited by 1
Association between dietary inflammatory index and hepatic steatosis: cross-sectional evidence from the NHANES 2007–2020
Wu, Z., Liang, Y., Zeng, L., Fang, J., & He, J. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01015-w · Cited by 1
Membrane attack complex impairs hepatocyte autophagy in alcohol-related liver disease by regulating the SIRT1-FOXO3 signaling
Hu, Z., Jiang, S., Wan, Z., Luo, L., Wang, M.-L., Qiu, H., Wang, Y., Liu, Y., & Shan, R. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114713 · Cited by 1
Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases
Pugliese, N., Spertino, M., Mercurio, M., Ciardullo, S., Perseghin, G., Hassan, C., Vettor, R., Petta, S., & Aghemo, A. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.10.018 · Cited by 2
Research and clinical trial design in patients with metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD): a narrative review
Acuña, P., ALBHAISI, O. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Díaz, L. A., & Arab, J. P. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.61 · Cited by 2
Self-citation
Stable Nationwide Sepsis-Related Mortality Does Not Extend to Individuals with Alcohol-Associated Liver Disease
Danpanichkul, P., Duangsonk, K., Faulkner, C., Sirimangklanurak, S., Sodsri, T., Polpichai, N., Chan, S., Pang, Y., Mousa, O. Y. S., Kim, D., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09604-9 · Cited by 1
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
Danpanichkul, P., Blaney, H. L., Perelli, J., Huerta, P., Idalsoaga, F. J., Arrese, M. A., Arab, J. P., Loomba, R. S., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.32 · Cited by 1
Self-citation
Longitudinal analysis of pain symptoms and risk factors in patients with incident liver disease: a nationwide cohort study
Pu, K., & Zhu, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04003-w · Cited by 1
Steatotic liver disease in Latin America: current views and perspectives
Idalsoaga, F. J., Díaz, L. A., Francisco Barrera, M., Gadano, A. C., de Oliveira, C. P. M. S., Arab, J. P., & Arrese, M. A. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01219-3 · Cited by 1
Self-citation
GPAM mediates mitochondrial dysfunction and the progression of alcoholic liver disease through lipid remodeling
Zhan, Z., Liu, X., Li, Z. H., Qiao, X., Li, S., Gong, Y., Yang, L., Gao, Y., Xia, X., Bai, K., et al. (2026) · Science Advances · doi:10.1126/sciadv.aef1896 · Cited by 1
Food and nutrition literacy and diet self-efficacy among patients with liver cancer: latent profile analysis, associated factors, and an exploratory examination of gender differences
Liu, Z., She, T., Mo, S., Wei, W., Guo, Y. H., Liu, Y., & Zhang, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1839963 · Cited by 1
Silymarin-loaded phytosomal nanoparticles mitigate dyslipidemia, oxidative damage, and hepatic injury in high-fat diet-induced metabolic dysfunction-associated steatotic liver disease in rats
Kattan, S. W., Almars, ‏. I., Tounsi, W. A., Turkistani, A. A., Mohamed, A. M. E. A., Elghareeb, M. M., Elmorsy, E. M., & Ali, S. H. E. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05004-z · Cited by 1
Challenges in the management of alcohol-associated liver disease in Latin America
Idalsoaga, F. J., Díaz, L. A., Ayares, G., Arrese, M. A., & Arab, J. P. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101748 · Cited by 2
Self-citation
Effects of alcohol consumption on the prevalence and incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis
Yuan, J., Chen, Z., Gu, Y., Liang, Y., & Yao, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0330105 · Cited by 1
Interleukin-mediated therapies in liver diseases and comorbidity effects
Bouare, N., & Delwaide, J. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i7.980 · Cited by 1
Enhancing the functionality of mesenchymal stem cells: An attractive treatment strategy for metabolic dysfunction-associated steatotic liver disease?
Shan, X., & Zhao, L. (2024) · World Journal of Stem Cells · doi:10.4252/wjsc.v16.i10.854 · Cited by 1
Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Yoon, E. L., & Jun, D. W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0500
Impact of low alcohol consumption in the natural history of cirrhosis
Aguado, D. M., & Vilar‐Gómez, E. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-615
Editorial: Metabolic Dysfunction and Alcohol—Two Sides of the Same Coin
Ayares, G., & Díaz, L. A. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18323
Self-citation
Metabolic and Alcohol-associated Liver Disease and its Place in the Spectrum of Steatotic Liver Disease
Rutledge, S. M., & Im, G. Y. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102545
Oral Delivery of Chitosan-Bilirubin Nanoparticles Alleviates Hepatic Inflammation and Fibrosis in Metabolic Dysfunction-Associated SteatohepatitisPreprint
Jon, S., Rahman, A. T., Choi, J., Kyung, W., Kang, S., & Lee, S. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5244382
Association Between Skeletal Muscle Mass and Fatty Liver Index; Insights From NHANES (2017–2020)Preprint
Lei, D., Ma, X., Chen, L., Zhao, Y., Lan, D., Rong, R., Zhou, L. M., & Yang, F. (2025) · Research Square · doi:10.21203/rs.3.rs-6260691/v1
Controversias en la nomenclatura: de la esteatohepatitis no alcohólica al espectro completo de la esteatosis hepática
Romero‐Gómez, M., Ferretti, S. E., & Arab, J. P. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107044
Self-citation
First-in-class drug oroxylin A tablets for treating hepatic and gastrointestinal disorders: from preclinical development to clinical research
Luo, C., Li, X., Gao, Y., Yang, J., Fang, W., & Wei, L. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60910-1
Controversies in nomenclature: From nonalcoholic steatohepatitis to the full spectrum of hepatic steatosis
Romero‐Gómez, M., Ferretti, S. E., & Arab, J. P. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107044
Self-citation
Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1
Xiao, L., Li, L., Wu, S., Che, Z., Du, Y., Zheng, J., Yan, J., Wang, H., Zhang, H., Li, Y., et al. (2026) · eLife · doi:10.7554/elife.109174.4
Alcohol and liver physiology
Gallegos, E. M., Couvillion, K. E., & Simon, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34258-5.00004-9
Natural history and outcomes of MASLD and MetALD following non-alcoholic fatty liver disease reclassification in a Canadian cohort
Almahanna, Y., Idalsoaga, F. J., Díaz, L. A., Almohsen, A., Song, Y. N., Bajunayd, A., Mortuza, R., Kim, J., Abaya, A., Khan, M. Q., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102166
Self-citation
Functional food potential of Cornus officinalis for liver health: mechanistic evidence and perspectives
Liu, B., He, Y., Ma, X., Zhao, C., Chen, Q., Li, Y.-X., Heng, J., Zhang, Y., Jin, J., & Wang, F. (2025) · Food Science and Human Wellness · doi:10.26599/fshw.2025.9250842
Severe Alcoholic Hepatitis in a Young Adult Survivor of Childhood Leukemia : Synergistic Impact of Moderate Alcohol Intake and Metabolic Dysfunciton
Sazhnyev, Y., Wang, M. L., & Chu, G. (2025) · International Conference on Intelligent Informatics and Biomedical Sciences (ICIIBMS) · doi:10.1109/iciibms66230.2025.11316702
Beneficial Effect of Nutraceuticals on Liver Diseases
Sarkar, S., Gupta, P., Nandi, G., Sahu, R., Paul, P., Dua, T. K., & Manna, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898813369126010008
Deep Learning-Assisted Metasurface-Enhanced Near-Infrared Spectroscopy for Alcohol DetectionPreprint
Xia, Y., Wang, Q., liu, G., Gong, Z., Liu, B., Huang, Y., Wang, Y., Li, Y., Liu, H., & Zhang, X. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6156531
Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1Preprint
Xiao, L., Li, L., Wu, S., Che, Z., Du, Y., Zheng, J., Yan, J., Wang, H., Zhang, H., Li, Y., et al. (2026) · eLife · doi:10.7554/elife.109174.1
Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1Preprint
Xiao, L., Li, L., Wu, S., Che, Z., Du, Y., Zheng, J., Yan, J., Wang, H., Zhang, H., Li, Y., et al. (2026) · eLife · doi:10.7554/elife.109174
Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction–associated steatotic liver disease and its progression to hepatocellular carcinoma
Kouti, T., Christodoulou, P., Christodoulides, S., Protopapa, F., Michaeloudes, C., & Farazi, P. A. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1767917
Phenotype-specific Inflammatory Signatures in Steatotic Liver Disease: Implications for Precision Medicine in Hepatology
Soni, K., Arab, J. P., & Díaz, L. A. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103501
Self-citation
TRPA1 Expressed by Hepatocytes and Liver Macrophages Does Not Mediate Inflammatory Infiltration and Steatosis in a Mouse Model of Chronic Alcohol-Induced Liver Injury
Fehér, D. L., Al-Omari, A., Sándor, Z., Hegedüs, D., Gaszner, B., Szombati, V., Fincsúr, A., & Kormos, V. (2026) · Cells · doi:10.3390/cells15050423
Progression of FIB-4 index predicts major adverse cardiovascular events in patients with metabolic dysfunction
Idalsoaga, F. J., Cambindo, V., Fuentes–López, E., Dukes, E., Ibáñez, S., Hunfan, P., Mollo, C., González, J., Ayares, G., Ramírez, C., et al. (2026) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502608
Self-citation
Hepatoprotective Potential of Boerhavia diffusa L. Against Alcohol‐Induced Toxicity in HepG2 Cells: An In Vitro and In Silico Study
Deshmukh, K. N., Kendre, A. G., Srivastava, A., Goyal, A., Bharatam, P. V., & Jachak, S. M. (2026) · ChemistrySelect · doi:10.1002/slct.202503437
Comparison of the identification and practicability of non-invasive diagnostic indicators under NAFLD, MAFLD and MASLD in China: a cross-sectional study
Tan, X., Zou, H., Huang, X.-J., Guo, M., Yu, R., Liu, X., Peng, T., Yang, X., & Qin, C.-S. (2026) · BMJ Open · doi:10.1136/bmjopen-2024-094809
Study of Gut Microbiota in Metabolic Dysfunction-Associated Fatty Liver Disease
陈嘉璐 (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641354
Hepatoprotective effects of pentadecanoic acid-rich microalgae Melosira nummuloides in a high-fat diet-induced mouse model of non-alcoholic fatty liver disease
Kim, D. K., Rajan, P., Cuong, D. M., Yoon, T. H., Yang, S. H., Oyinloye, K. R., Go, G. M., & Cho, S. K. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107311
Deep learning-assisted metasurface-enhanced near-infrared spectroscopy for alcohol detection
Xia, Y., Wang, Q., Liu, G., Gong, Z., Liu, S., Huang, Y., Wang, Y., Li, Y., Liu, H., & Zhang, X. (2026) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2026.128007
Steatotic liver disease: a dynamic spectrum, not a static state
Spearman, C. W. (2026) · South African journal of gastroenterology and hepatology. · doi:10.36303/sajgh.4337
Liver Endothelial Heg1 Signal Limits Hepatic Steatosis via Wnt-Mediated Fatty Acid Oxidation in Hepatocytes
Rao, X., Zhao, Q., Chen, J., Zheng, M., Xing, M., Feng, Y. Y., Chen, J., Zhu, S., Han, Z., McCaughan, G. W., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101807 · Cited by 1
Hepatic Hamp restoration contributes to nicotinamide mononucleotide (NMN)-alleviated hepatic steatosis in chronic alcohol-fed mice
Cao, F., Ge, X., Pi, A., Huang, Q., Pei, L., Chen, R., Cao, W., Ding, Q., Yang, M., Song, Q., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10398-3
Probiotic, synbiotic effects on the gut–liver axis: omics-enabled mechanisms and therapeutic windows
Oriquat, G., El‐Sehrawy, A. A. M. A., Abdulsahib, W. K., Mustafa, W. W., Jyothi, S. R., Nayak, P. P., Janney, J. B., Singh, G., Sinha, A., & Yazdi, F. (2026) · Future Microbiology · doi:10.1080/17460913.2026.2684877
MagmaFlow : A desktop platform for artificial intelligence‐driven expression analysis
Buss, C. E., Li, A., Gilglioni, E. H., Bansal, M., Singh, S. P., Bakiri, L., Cardozo, A. K., & Gurzov, E. N. (2026) · FEBS Open Bio · doi:10.1002/2211-5463.70288
Therapeutic Insights into the Hepatoprotective Effect of Strobilanthes callosa
Chauhan, D., Goel, F., & Garg, V. K. (2026) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-026-02100-5
Global trends in national alcohol control policies between 2010 and 2019
Gu, H., Fuentes–López, E., Idalsoaga, F. J., Aguado, D. M., Kamath, P. S., Singal, A. K., Bataller, R. A., Arrese, M. A., Agirre‐Garrido, L., White, T. M., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101938
Self-citation
Prognostic significance of prior alcohol use disorder in patients with presumed metabolic dysfunction‐associated steatotic liver disease: A large multi‐center cohort study
Fakhoury, B., Liu, J., Jahagirdar, V., Rama, K., Winder, G. S., Díaz, L. A., & Arab, J. P. (2026) · Addiction · doi:10.1111/add.70567
Self-citation
Liver transplantation in patients with metabolic dysfunction and alcohol-related liver disease (MetALD)
Coronel-Castillo, C. E., Parraga, X., Sierra, L., Arrese, M. A., Arab, J. P., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.78
Self-citation
The dynamic spectrum of steatotic liver disease: the global perspective
Younossi, Z. M., Zelber‐Sagi, S., Kalligeros, M., Wajcman, D. I., Henry, L. L., Grinshpan, L. S., Israelsen, M. E., Díaz, L. A., Fan, J., Arrese, M. A., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01235-3
Self-citation
Autophagy suppression is associated with enhanced preneoplastic hepatocellular lesions in rats fed a lard-containing high-fat diet
Karasawa, A., Takimoto, M., Sakamaki, Y., Shoubudani, M., Ohshima, K., Hara, E., Yidan, B., Luo, M., Todoroki, M., Kobayashi, M., et al. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116334
Activation of the KPNA2-mediated nuclear import of PPARα by KIF13B mitigates alcohol-associated liver steatosis
Lu, K., Mei, S., Zhang, L., Lian, L., Lu, Y., Xian, A., Shen, X., Zhang, X., Zhao, Y., Tao, Y., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-339656
Ethanol reshapes FFC-driven steatohepatitis through time-dependent fibrosis and lipid-droplet remodeling
Weninger, J., Lee, A. L., Marek, G. W., Lange, N. F., Mauer, A. S., Puri, G., Shah, V. H., & Malhi, H. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2026
Weakly supervised deep learning distinguishes alcohol-associated from metabolic dysfunction-associated steatohepatitis on H&E whole-slide images
Meroueh, C., Ibrahim, S. H., Tizhoosh, H., Noh, Y., Kim, I. Y., Lucas, P., & Shah, V. H. (2026) · Journal of Pathology Informatics · doi:10.1016/j.jpi.2026.100712
Application of artificial intelligence in hepatology
Hu, Z., Lin, Y., Gao, H., Shuai, L., Tong, Z., Nie, C., Yang, Z., & Zhao, J. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1851723
AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction– and Alcohol-Associated Liver Disease: Expert Review
Arab, J. P., Malhi, H., Winder, G. S., & Fontana, R. J. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.07.027
Self-citation

Authors: Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M.
Affiliations: Pontificia Universidad Católica de Chile (CL)
Western University (CA)
Inserm (FR)
Corresponding author: Arrese, Marco
ORCID: Díaz, Luis Antonio
Arab, Juan Pablo
Louvet, Alexandre
Arrese, Marco
Venue: Nature Reviews Gastroenterology & Hepatology
Publisher: Springer Science and Business Media LLC
Published: 2023-08-15
Volume: 20
Issue: 12
Pages: 764-783
ISSN: 1759-5045 (ISSN-L)
1759-5053
DOI: 10.1038/s41575-023-00822-y
OpenAlex: W4385851156
Semantic Scholar: f457122280dbd0b72d6e068cbffa2b2fe281bb04
Cited by: 207
References: 252
Citations by year: 2026: 58 · 2025: 75 · 2024: 63 · 2023: 11
FWCI: 8.06
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Gastroenterology & Hepatology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (U01AA021908, U01AA020821)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: non-alcoholic fatty liver disease, alcoholic liver disease, metabolic syndrome, hepatic steatosis, alcohol consumption, alcohol biomarkers, disease classification, pathogenesis, chronic liver disease
MeSH terms: Alcohol Drinking, Ethanol, Humans, Biomarkers, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks